Renin-sensitive microRNAs correlate with atherosclerosis plaque progression

Journal of Human Hypertension

Volumn 28, Issue 4, 2014, Pages 251-258

  Deiuliis, J ^a   Mihai, G ^a   Zhang, J ^b   Taslim, C ^b   Varghese, J J ^a   Maiseyeu, A ^a   Huang, K ^b   Rajagopalan, S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aliskiren; atherosclerosis; blood monocyte microRNA; clinical trial; MRI; renin inhibition

Indexed keywords

ALISKIREN; MICRORNA; PLACEBO; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ABDOMINAL AORTA; ADULT; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RADIOCARDIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION; SINGLE BLIND PROCEDURE; THORACIC AORTA; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG EFFECTS; HYPERTENSION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

AMIDES; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; MICRORNAS; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; RENIN; SIGNAL TRANSDUCTION;

EID: 84896315902     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.97     Document Type: Article

References (32)

1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angio-tensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-153.
3. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37(4): 1047-1052.
4. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides 2011; 32(10): 2141-2150.
5. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24(2): 243-256.
6. Fisher ND, Meagher EA. Renin inhibitors. J Clin Hypertens 2011; 13(9): 662-666.
7. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008; 52(3): 563-572.
8. Lu H, Rateri DL, Feldman DL, Charnigo Jr RJ, Fukamizu A, Ishida J et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118(3): 984-993.
9. Kuhnast S, van der Hoorn JW, van den Hoek AM, Havekes LM, Liau G, Jukema JW et al. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvas-tatin. J Hypertens 2012; 30(1): 107-116.
10. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13(3): 387-393.
11. Mihai G, Varghese J, Kampfrath T, Gushchina L, Hafer L, Deiuliis J et al. Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial. J Am Heart Assoc 2013; 2(3): e004879.
12. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281(27): 18277-18284.
13. Nossent AY, Hansen JL, Doggen C, Quax PH, Sheikh SP, Rosendaal FR. SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens 2011; 24(9): 999-1006.
14. Sober S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 2010; 391(1): 727-732.
15. Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 2010; 285(16): 11903-11912.
16. Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension 2011; 58(6): 1093-1098.
17. Mihai G, Chung YC, Kariisa M, Raman SV, Simonetti OP, Rajagopalan S. Initial feasibility of a multi-station high resolution three-dimensional dark blood angiography protocol for the assessment of peripheral arterial disease. J Magn Reson Imaging 2009; 30(4): 785-793.
18. Mihai G, Chung YC, Merchant A, Simonetti OP, Rajagopalan S. T1-weighted-SPACE dark blood whole body magnetic resonance angiography (DB-WBMRA): initial experience. J Magn Reson Imaging 2010; 31(2): 502-509.
19. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26(3): 317-325.
20. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
21. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets 2010; 11(8): 943-949.
22. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008; 79(4): 581-588.
23. Liu T, Shen D, Xing S, Chen J, Yu Z, Wang J et al. Attenuation of exogenous angiotensin II stress-induced damage and apoptosis in human vascular endothelial cells via microRNA-155 expression. Int J Mol Med 2013; 31(1): 188-196.
24. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356(13): 1304-1316.
25. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299(13): 1561-1573.
26. Cai K, Wang Y, Bao X. MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. J Exp Clin Cancer Res 2011; 30: 73.
27. Liu Z, Yang D, Xie P, Ren G, Sun G, Zeng X et al. MiR-106b and MiR-15b modulate apoptosis and angiogenesis in myocardial infarction. Cell Physiol Biochem 2012; 29(5-6): 851-862.
28. Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 2008; 68(20): 8191-8194.
29. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC et al. The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012; 31(50): 5162-5171.
30. Singh NN, Ramji DP. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006; 17(6): 487-499.
31. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem 2012; 287(26): 21816-21825.
32. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SL, Wong MT et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 2012; 97(12): E2271-E2276.